List of Sublocade drug patents
Sublocade is owned by Indivior Inc.
Sublocade contains Buprenorphine.
Sublocade has a total of 11 drug patents out of which 0 drug patents have expired.
Sublocade was authorised for market use on 30 November, 2017.
Sublocade is available in solution, extended release;subcutaneous dosage forms.
Sublocade can be used as treating addiction with 100 mg or 300 mg dose of buprenorphine; treating opioid addiction by administering buprenorphine; treating addiction by once per month administration of buprenorphine; treating addiction by subcutaneous injection of buprenorphine, treating opioid addiction by administering buprenorphine; treating opioid addiction by administering buprenorphine once per month; treating opioid addiction by administering buprenorphine composition with 28 day dose duration; treating opioid addiction by subcutaneous injection of buprenorphine, treating opioid dependency by administering buprenorphine once per month; treating opioid dependence by administering buprenorphine, treating opioid use disorder, treating opioid dependency by administering buprenorphine; treating opioid dependency by administering buprenorphine once monthly, in situ formation of solid buprenorphine composition, treating opioid dependency by administering buprenorphine; treating opioid addiction by administration of buprenorphine; treating opioid dependency by subcutaneously administering buprenorphine; treating opioid addiction by 100 mg or 300 mg dose buprenorphine; treating opioid dependency by administering buprenorphine once per month, treatment of moderate to severe opioid use disorder.
The generics of Sublocade are possible to be released after 22 June, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10198218 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US9272044 | INDIVIOR INC | Injectable flowable composition buprenorphine |
Jun, 2031
(8 years from now) | |
| US9498432 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US10592168 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US9827241 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US9782402 | INDIVIOR INC | Injectable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US10558394 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(8 years from now) | |
| US8975270 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Sep, 2031
(8 years from now) | |
| US8921387 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jan, 2032
(8 years from now) | |
| US11000520 | INDIVIOR INC | Buprenorphine dosing regimens |
Nov, 2035
(12 years from now) | |
| US10646484 | INDIVIOR INC | Methods to treat opioid use disorder |
Jun, 2038
(15 years from now) | |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treatment of moderate to severe opioid use disorder; Treating opioid addiction by administering buprenorphine; Treating opioid addiction by administering buprenorphine once per month; Treating opioid addiction by administering buprenorphine composition with 28 day dose duration; Treating opioid addiction by subcutaneous injection of buprenorphine; In situ formation of solid buprenorphine composition; Treating opioid dependency by administering buprenorphine; Treating opioid addiction by administration of buprenorphine; Treating opioid dependency by subcutaneously administering buprenorphine; Treating opioid addiction by 100 mg or 300 mg dose buprenorphine; Treating opioid dependency by administering buprenorphine once per month; Treating addiction with 100 mg or 300 mg dose of buprenorphine; Treating addiction by once per month administration of buprenorphine; Treating addiction by subcutaneous injection of buprenorphine; Treating opioid dependency by administering buprenorphine once monthly; Treating opioid dependence by administering buprenorphine; Treating opioid use disorder
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic